DINAS‐AR was a national prospective observational study to assess the unmet needs in patients with type 2 diabetes treated with basal insulin with or without oral antihyperglycaemic drugs and/or GLP‐1 receptor agonist. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.